Affiliation:
1. Sağlık Bilimleri Üniversitesi YGHH EAH
2. UNIVERSITY OF HEALTH SCIENCES, İSTANBUL YEDİKULE HEALTH RESEARCH CENTER FOR PULMONOLOGY AND THORACIC SURGERY, DEPARTMENT OF INTERNAL MEDICINE
3. ÜSKÜDAR ÜNİVERSİTESİ
Abstract
Aim: In the clinical course of Chronic Obstructive Pulmonary Disease (COPD), exacerbations that
are defined as worsening of respiratory symptoms (dyspnoea, cough, sputum production) may occur,
which causes poor prognosis and require additional treatments. Cost-effective mortality predictors are
valuable for the treatment management of COPD. We aimed to investigate whether serum uric acid
(UA) and serum uric acid to creatinine ratio (UCR) are predictors of mortality and hypoxemia in patients
with acute exacerbations of COPD (AECOPD).
Material and Methods: 105 patients with AECOPD who were hospitalized in a reference chest hospital
between January 2014 and December 2018 were evaluated retrospectively in this cross-sectional study.
The associations between UA and UCR and long-term mortality, hypoxemia, comorbidity, FEV1 value,
and Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary
Disease (GOLD) stage were analyzed.
Results: In the present study including 105 patients with AECOPD (97 males, mean age of 65±9 years),
a significant correlation was found between hyperuricemia and mortality (95% CI:1.15-10.72, p=0.027;
95% CI:1.16-4.12, p=0.016, respectively), while no correlation was found between UCR and mortality
(p=0.051, p=0.053, respectively). Low UA level was associated with hypoxemia significantly (p=0.022),
but no association was observed between UCR and hypoxemia (p=0.094).
Conclusion: It appears that UA is more important for predicting long-term mortality in patients with
AECOPD than UCR. We suggest that UA can be used as a biomarker of long-term mortality for the
identification of high-risk COPD patients that require frequent clinical follow-up and intense treatment
management.
Publisher
Bulent Evcevit University
Reference29 articles.
1. Referans1 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available from: http://www.goldcopd.org/Guidelines/guidelines-resources.html (2021, accessed 1 July 2014).
2. Referans2 Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(5 Pt 1): 1418-1422.
3. Referans3 Nicks ME, O’Brien MM, Bowler RP. Plasma antioxidants are associated with impaired lung function and COPD exacerbations in smokers. COPD 2011; 8(4): 264-269.
4. Referans4 Parker CM, Voduc N, Aaron SD, et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26(3): 420-428.
5. Referans5 Barbara JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997; 10(6): 1285-1291.